Analysis

Magic Johnson Backs Record $12.5B Lakers Deal as MSGS Gap Nears $3.7B

Magic Johnson endorses the record $12.5B Lakers sale, while MSGS trades at a $3.7B discount to private valuations, with Rangers spin-off due by end of October.

Daniel Marsh · · · 3 min read · 14 views
Magic Johnson Backs Record $12.5B Lakers Deal as MSGS Gap Nears $3.7B
Mentioned in this article
MSGS $407.17 -1.41%

Los Angeles, August 17, 2026 – The planned $12.5 billion acquisition of the Los Angeles Lakers by former Disney CEO Bob Iger and investor Joshua Kushner has set a new benchmark for U.S. sports franchise valuations. The deal, which is pending NBA approval and due diligence, represents a 25% increase over the $10 billion valuation agreed upon just 14 months ago. Magic Johnson, the Lakers legend, voiced his support, saying, “Laker fans, you couldn’t have two better owners.”

The transaction has significant implications for public markets, particularly for Madison Square Garden Sports Corp. (NYSE: MSGS), which owns the New York Knicks and Rangers. MSGS shares closed Friday at $407.17, giving the company a market capitalization of approximately $9.8 billion. Analysts estimate the combined private value of the Knicks and Rangers at $13 billion to $14 billion, implying a discount of roughly $3.7 billion—or 27.4%—between the public market valuation and private benchmarks.

This gap has widened following the Lakers’ record price, which underscores the scarcity value of premier sports franchises. The Lakers deal is 20% higher than the $10 billion paid for the team in 2025, and far exceeds other recent transactions, including the Boston Celtics’ $6.1 billion transfer (51% lower) and the Charlotte Hornets’ $3 billion sale (76% lower).

For MSGS, the Lakers deal serves as a fresh data point in the ongoing debate over the value of its teams. Optimists argue that MSGS shares should trade closer to the private valuation, while skeptics point to factors such as James Dolan’s voting control, tax implications, and the complexity of the arena deals that could justify a discount.

The company is moving to unlock value through a spin-off of the Rangers from the Knicks, a transaction expected to be completed by the end of October. Shareholders will receive shares in the new Rangers entity on a pro rata basis, and the deal is intended to be tax-free. This separation will allow investors to value each franchise independently, potentially narrowing the gap.

MSGS’s recent financial performance has been strong, with quarterly revenue up 37% year-over-year, driven by playoff ticket sales and merchandise. Average playoff revenue reached $20.2 million per game, and season-ticket renewals are expected to exceed 90% for the upcoming fiscal year. Chief Operating Officer Jamaal Lesane highlighted the sustained demand, which supports recurring cash flows.

Despite these positives, MSGS’s stock has not fully reflected the private market optimism. Analyst price targets range from $430 to $522, implying upside of 5.6% to 28.2% from Friday’s close. The immediate focus on Monday will be whether MSGS can hold its $407.17 level, as premarket trading indicates further declines.

The Lakers deal is still subject to due diligence and NBA approval, and there is no guarantee it will close. Similarly, MSGS’s spin-off is contingent on board and league approvals. Risks include lower ticket sales, rising player costs, and declines in media-rights revenue, which could impact cash flow and valuations.

Investors will be watching for any updates on the Lakers transaction and the progress of the Rangers separation as the end-of-October target date approaches. The outcome of these events could significantly influence MSGS’s market valuation and investor sentiment in the sports and entertainment sector.

This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Market data may be delayed. Always conduct your own research and consult a licensed financial advisor before making investment decisions.

Related Articles

View All →